Skip to main content
Fig. 3 | Lipids in Health and Disease

Fig. 3

From: Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients

Fig. 3

IL-17A mAb ameliorates dysregulated lipid metabolism in psoriasis patients. a. Heatmap of the 43 identified differential metabolites in the study cohort 1. The color represents the average normalized intensity of each metabolite. b. Box plots of highlighted metabolites in study cohort 1. *P < 0.05, **P < 0.01, ***P < 0.001. c. Correlation analysis between the identified DAs and PASI scores of psoriasis patients in study cohort 1. CON: group of healthy controls; PSO: group of psoriasis patients; IXE: group of ixekizumab-treated psoriasis patients; PASI: psoriasis area and severity index

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X